BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.

BioNTech will present clinical data at ASCO 2026 showing encouraging anti-tumor activity for pumitamig in combination with chemotherapy across multiple cancer types, and positive overall survival data for gotistobart in platinum-resistant ovarian cancer. The company is advancing 25+ Phase 2/3 trials including 13 pivotal trials across its diversified oncology pipeline.

BioNTech will present clinical data at the 2026 ASCO Annual Meeting on late-stage oncology pipeline programs, including positive Phase 2 data from ROSETTA Lung-02 for Pumitamig (in combination with chemotherapy for non-small cell lung cancer) and overall survival data for Gotistobart in platinum-resistant ovarian cancer. The company is advancing a diversified portfolio with over 25 Phase 2/3 clinical trials, including 13 ongoing registration-relevant studies.

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

Bristol Myers Squibb trades at $55.67 with concerns about upcoming patent cliffs for its top-selling drugs Opdivo and Eliquis. However, the company's newer drug portfolio and promising pipeline, including Milvexian and Pumitamig, could offset these losses. Trading at 9x forward earnings versus the healthcare sector average of 16.8x, the stock appears attractively valued for long-term investors seeking both growth and a 4.5% dividend yield.

BioNTech stock declined 3% after reporting Q1 revenues of €118.1 million, missing consensus estimates due to lower COVID-19 vaccine sales. The company posted a net loss of €531.9 million and announced a major restructuring plan involving the closure of manufacturing sites in Germany and Singapore, targeting €500 million in annual cost savings by 2029. The company maintained its FY2026 revenue guidance of €2-2.3 billion.

Moderna shares fell 2.05% on Friday despite beating revenue expectations with $389 million (vs. $227.97M consensus) and reporting a narrower adjusted loss of $1.18 per share. The decline was driven by a $2.22 per share litigation settlement charge. The company reiterated 2026 revenue growth guidance of up to 10% and announced progress on its H5 pandemic flu vaccine candidate with a Phase 3 trial launch.

Inventiva announced the recruitment of three new senior executives: Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These appointments strengthen the company's leadership team ahead of the anticipated Phase 3 top-line data readout for lanifibranor in Q4 2026. Previous CFO Jean Volatier will transition to EVP Finance & Corporate Social Responsibility.

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Anaveon, a late-stage preclinical biotech company focused on immune system reprogramming, announced the appointment of Thaminda Ramanayake as CEO. Ramanayake brings over 20 years of biopharmaceutical leadership experience, including roles at CureVac, Sanofi, BioMarin, and Amgen. He will lead Anaveon's advancement of its immunology pipeline toward clinical development, with ANV200 as the lead asset for T cell depletion in autoimmune and inflammatory diseases.

BioNTech shares plummeted 17.67% after the company issued weaker-than-expected 2026 revenue guidance of $2.2-$2.5 billion, citing normalized Covid vaccine sales. Co-founders Ugur Sahin and Ozlem Tureci plan to exit by end of 2026 to launch a new mRNA firm, while the company pivots toward capital-intensive oncology development. Despite maintaining a strong €16 billion cash position, investors are concerned about leadership continuity and the multi-year investment phase before oncology revenue contributions materialize.